Lancet: Fremangezumab for stubborn migraine prevention

Targeting calcitonin gene-related peptides (CGRP) showed better migrainepreventeffectThe researchers examined the effectiveness and tolerance of the fully human-derived CGRP antibody Fremantezumab in previous treatments of non-responsive 2-4 migrainesthis Phase III study recruited patients between the ages of 18 and 70 with intermittent or chronic migraines who had received 2-4 types of migrainepreventiondrugs over the past 10 yearsPatients were randomly injected once quarterly fremanezumab (1st month, 675 mg; 2nd and 3rd months: placebo), fremanezumab once a month (first month: 225 mg for occasional migraine patients, 675 mg for chronic migraine patients; 225 mg for the second and third months) or placeboThe main result of the study was a change in the average number of migraine days per month during the 12-week period of treatment838 patients participated in the study, including 329 cases of occasional migraines (39%), 509 cases of chronic migraines (61%), divided into placebo group (n?279), quarterfre Fremanezumab group (n-276) or monthly Fremanezumab group (n-283)During the 12 weeks, the average number of migraine days per month in the treatment group decreased significantly compared to placebo (compared to placebo, the quarterly group had a difference of -3.1 lSM and the monthly group was -3.5)The difference in the rate of adverse events between groups was not significantstudy suggests that Fremangezumab still has a good preventive effect on migraine patients who have previously failed multiple medications